Novartis AG agreed to pay $390 million to resolve a lawsuit claiming the company paid kickbacks to increase sales of several prescription drigs. The payment covers all claims related to the medicines Myfortic, Exjade, Tasigna, Gleevec and TOBI, the company said. The U.S. had sought as much as $3.3 billion from Novartis for Exjade and Myfortic claims, claiming it had referred patients to specialty pharmacies and paid kickbacks in the form of rebates to get those pharmacies to recommend the drugs to patients and to increase sales. “Novartis announced that it reached a settlement in principle with the U.S. Department of Justice, the states and the relator in the suit related to the company’s interactions with specialty pharmacies,” the Basel, Switzerland-based drugmaker said in a statement released with its third-quarter earnings.